Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid

C. Mulder, L. O. Wahlund, M. Blomberg, S. De Jong, G. J. Van Kamp, P. Scheltens, T. Teerlink*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Nitric oxide (NO) may play a role in the pathophysiology of Alzheimer's disease (AD). Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, is involved in regulation of NO production. Recently it has been reported that dimethylarginine dimethylaminohydrolase, an enzyme that hydrolyses ADMA into citrulline and dimethylamine, is specifically elevated in neurons displaying cytoskeletal abnormalities and oxidative stress in AD. We hypothesized that this could lead to altered CSF concentrations of ADMA in AD. Measurement of ADMA and dimethylamine in CSF revealed no significant differences between AD patients (n = 20) and age-matched control subjects (n = 20). Our results suggest that in early stages of AD overall regulation of NO production by ADMA is not aberrant.

Original languageEnglish
Pages (from-to)1203-1208
Number of pages6
JournalJournal of Neural Transmission
Issue number9
Publication statusPublished - 23 Sep 2002

Cite this